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Abstract: Background and aims: Dietary studies have shown that active biopeptides provide protective
health benefits, although the mediating pathways are somewhat uncertain. To throw light on
this situation, we studied the effects of consuming Spanish dry-cured ham on platelet function,
monocyte activation markers and the inflammatory status of healthy humans with pre-hypertension.
Methods: Thirty-eight healthy volunteers with systolic blood pressure of >125 mmHg were enrolled
in a two-arm crossover randomized controlled trial. Participants received 80 g/day dry-cured pork
ham of >11 months proteolysis or 100 g/day cooked ham (control product) for 4 weeks followed by
a 2-week washout before “crossing over” to the other treatment for 4 more weeks. Soluble markers and
cytokines were analyzed by ELISA. Platelet function was assessed by measuring P-selectin expression
and PAC-1 binding after ADP (adenosine diphosphate) stimulation using whole blood flow cytometry.
Monocyte markers of the pathological status (adhesion, inflammatory and scavenging receptors)
were also measured by flow cytometry in the three monocyte subsets after the interventional period.
Results: The mean differences between dry-cured ham and cooked ham followed by a time period
adjustment for plasmatic P-selectin and interleukin 6 proteins slightly failed (p = 0.062 and p = 0.049,
respectively), notably increased for MCP-1 levels (p = 0.023) while VCAM-1 was not affected. Platelet
function also decreased after ADP stimulation. The expression of adhesion and scavenging markers
(ICAM1R, CXCR4 and TLR4) in the three subsets of monocytes was significantly higher (all p < 0.05).
Conclusions: The regular consumption of biopeptides contained in the dry-cured ham but absent in
cooked ham impaired platelet and monocyte activation and the levels of plasmatic P-selectin, MCP-1
and interleukin 6 in healthy subjects. This study strongly suggests the existence of a mechanism that
links dietary biopeptides and beneficial health effects.
Keywords: dry-cured ham; active biopeptides; molecular markers; inflammation; platelet function;
monocyte
1. Introduction
The food industry sector is well aware of the well-documented positive effects of functional
foods or nutraceuticals on diverse physiological functions, apart from their nutritional properties [1].
Improvements in diet and lifestyle to reduce or prevent specific pathological processes such as
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cardiovascular disease (CVD) have become a goal amongst the general public. Within the last
decade, significant improvements in biomarkers related to CV health following the consumption
of nutraceuticals—particularly biopeptides—have been described in animal models [2–4].
Cardiovascular disease is the leading cause of human mortality and complications worldwide.
Hypertension is a well-known clinical risk factor for CVD. Cross-talk between platelets and monocytes
is regarded as a crucial pathophysiological mechanism linking thrombosis and inflammation and is
believed to mediate, at least in part, the pro-inflammatory action of activated platelets [5]. Experimental
data have found that activated platelets enhance cytokine production by monocytes [6] as well as
their receptor expression (ICAM-1R and VCAM-1R) and increase their adhesion to the blood vessel
wall [7]. However, the importance of monocytes/platelet phenotypical changes in human inflammatory
pathophysiology and hypertension remains unclear. Besides, there is limited data on the nutraceuticals
effects on inflammatory cells in humans. On the other hand, nutraceuticals such as biopeptides, sterols
or polyphenols have been shown to display activities that are beneficial to CV health in humans
in terms of blood pressure (BP), lipid metabolism and absorption, oxidative stress, inflammation
and haemostasis [8–11]. The potential health benefits of food-derived bioactive peptides have been
extensively reviewed [12,13].
Bioactive peptides are short sequences of 2–20 amino acid long residues that are absorbed through
the intestine and distributed through the circulation to produce a local or systemic physiological
effect. These peptides are released during food manufacturing, for instance important biochemical
changes occur with the curing of meat, including intense proteolysis by muscle peptidases [14,15].
Spanish dry-cured ham particularly, provides a valuable source of active biopeptides that have been
tested in vitro and in animal models of hypertension [16,17]. Besides, the results of a number of
studies suggest that dry-cured hams may be healthy and could be included as a regular component
of the diet [18]. However, any assessment of biological activity has almost exclusively been limited
to assays to detect the inhibition of angiotensin I-converting enzyme (ACE) [17] and few human or
mechanistic studies have been designed to explore the wider range of activities of such biopeptides in
the CV system. Therefore, the current study aims to establish cause–effect relationships between the
consumption of dry-cured ham containing bioactive peptides and any physiological effects observed
in individuals with pre-hypertension, looking for cellular changes related to the CV pathophysiology
other than just clinical parameters. In this study, we focus on changes in monocytes and platelets as
they are involved in inflammatory responses and the regulation of the thrombogenic status.
2. Material and Methods
2.1. Ethics Statement
The clinical study was registered in the Clinical Trials Database (ID: NCT02585089), performed
in accordance with the Helsinki Declaration and approved by the Ethics Committee of the Catholic
University of Murcia (UCAM, April 2015). All enrolled volunteers provided written informed consent.
2.2. Study Design and Subjects
In the context of the 7FP EU Beneficial Effects of Bioactive Compounds in Humans (BACCHUS)
project, a two-arm cross-over randomized control trial was assessed at the UCAM, between September
2015 and January 2016. Participants received 80 g/day dry-cured pork ham of >11 months
proteolysis (interventional product) and 100 g/day cooked ham (control product) each for 4 weeks.
After a two-week washout, the groups exchanged roles for another 4 weeks. The study arms were
similar for age, gender, ethnicity, body mass index and BP, which allowed comparisons to be made
between them. Thirty-eight apparently healthy Caucasian men and women from the University staff,
aged 40–55 years, in good general health and with pre-hypertension were recruited (systolic and
diastolic BPs above 125 and 80 mmHg, respectively).
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Exclusion criteria were smokers, Diabetes mellitus, diagnosed and treated hypertension, history
of cardiovascular events (stroke, myocardial infarction or peripheral vascular disease), cancer and
inflammatory diseases. Volunteers whose medications included anti-hypertensives, antiaggregants,
anticoagulants, antidepressants, anti-cholinergic or anti-spasmodic agents, the regular use of
medication affecting intestinal motility, vasodilators, lipid lowering therapies or fish oil supplements
(all other supplements were assessed on a case by case basis) were also excluded.
A list of restricted foods was given at the beginning of the study in order to avoid the excessive
consumption of salt and other cured meat products. Volunteers were asked not to change their dietary
patterns and lifestyle during the study. The individuals did not know about the purpose of the study
or which of the hams was supposed to be the interventional product. The volunteers were enrolled by
simple randomization by only one investigator and the randomization sequence was concealed until
the end of the statistical analysis.
2.3. Meat Products
Spanish dry-cured ham with a controlled salt content after >11 months dry-curing
process/proteolysis was the interventional product and cooked ham was the control product.
The Spanish dry-cured ham after an >11 month dry-curing process contained 25% less salt than
similar products on the market (4.38% vs. approx. 5.5%). As regard the cooked ham, it contained
2.61% salt, which was lower than the 3.6 g salt per 80 g intake of dry-cured ham. In order to counteract
the humidity and salt, a higher amount of cooked ham (control) was given (100 g/day). Hams were
manufactured and supplied by the local meat Company ElPozo Alimentación (Alhama de Murcia, Spain)
especially for the present clinical study in daily vacuum bags and labelled with safety information
(best by date, nutritional composition and storage information). The presence/absence of active
biopeptides in the meat products were tested and sequenced using one-dimensional reversed-phase
liquid chromatography combined with nano-liquid chromatography and an electrospray ionization
source coupled to a quadrupole time-of-flight mass spectrometer at the Instituto de Agroquímica y
Tecnología de Alimentos (CSIC, Valencia) [19] (Table 1).
Table 1. Analysis of Active Biopeptides in the Meat Products.
Active Biopeptides Dry-Cured Ham Cooked Ham
KAAAAP Identified N.D.
AAPLAP Identified N.D.
KPVAAP Identified N.D.
VPPAK Identified N.D.
KPGRP Identified N.D.
IAGRP N.D. N.D.
PAAPPK Identified N.D.
TGLKP N.D. N.D.
AAATP Identified N.D.
KAAAATP N.D. N.D.
N.D.: not detected.
2.4. Blood Sampling and Biochemical Determinations
For laboratory analysis, 8 h fasting peripheral venous blood samples were collected at four
time-points from all participants before and after each period (interventional/control product). Venous
blood was collected in EDTA and citrate (0.15%) Vacutainer® tubes. Blood was centrifuged at 3500 rpm
for 15 min at room temperature to obtain platelet-poor plasma. Plasma aliquots were stored at −70 ◦C
to allow ELISA batch analysis.
2.5. Flow Cytometry
(a) In vitro assessment of platelet activation:
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Freshly collected citrated blood (450 µL) was incubated with 0.02 mmol/L ADP (adenosine
diphosphate) for 2 min. Surface expression of membrane constitutive CD42a (GP IX) and platelet
activation markers (P-selectin and PAC-1 binding) were then assessed as already published [20].
After incubation, blood (5 µL) was labelled with 0.05 µg anti-CD42a-PerCP (clone Beb1),
anti-CD62P-APC (clone AK-4), PAC-1-FITC (clone PAC-1) (which recognizes the conformationally
activated GPIIβ/IIIα) (all from BD Biosciences, Oxford, UK) for 15 min, diluted with 1 mL filtered
PBS and then analyzed in a FACS Canto II flow cytometer (Becton Dickinson, Oxford, UK). Twenty
thousand platelets were counted in each sample run.
(b) In vitro assessment of monocyte activation:
Mouse anti-human monoclonal fluorochrome-conjugated antibodies against CD16-Alexa Fluor
488 (clone DJ130c, AbDSerotec, Oxford, UK), CD14-PerCP (clone MPf9, BD Biosciences, Oxford, UK)
were mixed in different tubes with 100 µL freshly collected EDTA blood. The above antibodies were
mixed with PE-conjugated antibodies against Toll-like receptor-4 (TLR4), intercellular cell adhesion
molecule-1 receptor (ICAM-1R) and CXCR4 (all from R&D Systems); APC-conjugated antibodies
against interleukin-6 receptor (IL6R), vascular cell adhesion molecule-1 receptor (VCAM-1R) and
CD163 (all from R&D Systems). After incubation for 15 min, red blood cells were lysed by 2 mL of
lysing solution® (BD Biosciences) for 15 min, diluted with PBS and immediately analyzed by flow
cytometry. Expression of the surface markers was quantified as mean fluorescence intensity (MFI)
on different monocyte subsets (CD14++CD16− (Mon1), CD14++CD16+ (Mon2), and CD14+CD16++
(Mon3)). The gating strategy excluded neutrophils, eosinophils, lymphocytes and other granulocytes
from the analysis (Figure 1). The method was assessed in a BD FACS Canto II flow cytometer (Becton
Dickinson, Oxford, UK) as previously described [21], acquiring 120.000 monocytes per sample.
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dotplot  to  select Eosinophils  (auto‐florescent  cells)  and Monocyte+Neutrophils,  clearly  separated 
from  the rest of  the blood cell subsets. Logical combination of  these gates allowed discrimination 
between Lymphocytes, Monocytes, Neutrophils and Esosinophils; (D) To identify the three monocyte 
subsets, a CD14/CD16 dotplot was used: Mon1 (CD14++CD16−, red), Mon2 (CD14++CD16+, green) 
and Mon3 (CD14+CD16++, blue); (E) Zoom area of mononuclear cells showing the three monocytes 
subsets clearly differentiated from lymphocytes and neutrophils. 
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Figure 1. Gating strategy to identify the three peripheral blood monocyte subsets (Mon1, Mon2 and
Mon3). (A) FSC/SSC- otplot was set to identify leukocytes and select lymphocyte ; (B) Leukocytes
were plotted in a SSC/CD14-dotplot to select high-SSC cells as Neutrophils+Eosinophils and
intermedia-SSC and CD14++/+/− as Monocytes; (C) Leukocytes were also plotted in a CD14/
CD16-dotplot to s lect Eosinophils (auto-florescent cells) and Monocyte+Neutrophils, clearly separated
from the rest of the blood cell subsets. Logical combination of these gates allowed discrimination
between Lymphocytes, Monocytes, Neutrophils and Esosinophils; (D) To identify the three monocyte
subsets, a CD14/CD16 dotplot was used: Mon1 (CD14++CD16−, red), Mon2 (CD14++CD16+, green)
and Mon3 (CD14+CD16++, blue); (E) Zoom area of mononuclear cells showing the three monocytes
subsets clearly differentiated from lymphocytes and neutroph ls.
2.6. Plasma Markers
Plasma samples (citrated and EDTA) were used to quantify the levels of soluble platelet and
monocyte adhesion mark rs (P-selectin and VCAM-1, respectively), high sensitive interleukin-6 (hs-IL-6)
and monocyte chemoattractant protein 1 (MCP-1) by enzyme-linked immunosorbent assay (ELISA).
All measurements were performed using recognized high quality human Affymetrix kits
(eBioscience, Carlsbad, CA 92008, USA): VCAM-1 antigen (Cat. No. BMS232), hs-IL6 antigen (Cat.
No. BMS213HS), P-selectin antigen (Cat. No. BMS219/4) and MCP-1 antigen (Cat. No. 88739922),
according to the manufacturer’s recommendations. The lower limits of detection of hs-IL-6, P-selectin,
VCAM-1 and MCP-1 were 0.03 pg/mL, 0.2 ng/mL, 0.6 ng/mL and 7 pg/mL, respectively.
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2.7. Statistical Analyses
Categorical variables are expressed as frequency (percentage) of volunteers. Continuous markers
are expressed as mean ± standard deviation (SD). Extremely skewed variables were Log transformed.
For each continuous marker, a regression of values after meat product consumption adjusted for values
before consumption was performed. By centering both variables on the mean before consumption,
the intercept of the model estimates the average change after consumption. The relative mean change
(mean change/mean before –1) was calculated in order to plot variables with different scales on the
same graph.
To estimate the differences of average changes between control and intervention groups, a binary
variable (control = 0, intervention = 1) was included in the model. Another binary variable was
included to adjust for the potential period effect. Furthermore, a random effect term by individual
was used to account for the repeated measures. We checked the model assumptions on the residuals
with plots and normality tests. R 3.3.1 software was used for the statistical analyses (R Foundation for
Statistical Computing, Vienna, Austria).
3. Results
Clinical characteristics, including demography and BP, of the study population, are shown in
Table 2. Thirty-eight subjects (44.3 ± 5.3 years old; 82% males) were included in the study. Readings of
systolic BP were above 125 mmHg, considered as normal-high blood pressure or pre-hypertension.
Table 2. Clinical Characteristics of Healthy Volunteers with Normal-High Hypertension.
n = 38 Volunteers
Age 44.3 ± 5.3
Gender (male) 82%
BMI, (kg/m2) 27.02 ± 3.9
Fat content, % 25.08 ± 7.3
Systolic BP, mmHg 137.4 ± 10.6
Diastolic BP, mmHg 80.0 ± 5.8
BMI: Body Mass Index; BP: Blood Pressure.
The baseline parameters of the participants were compared to data obtained after 4 weeks of
consuming dry-cured pork ham and cooked ham (Table 3). Body mass index and fat content were not
affected by the interventional product nor by the control product (p > 0.05, data not shown).
Table 3. Plasmatic Parameters with Volunteers in Both Trial Arms (Mean Difference After (1) Dry-Cured
Ham Intake, (2) Cooked Ham and (1–2) Difference).
n = 38 Period of
Intervention
Mean
Difference
Confidence Interval
p Value
Low 95% Upp 95%
Plasmatic markers, ELISA
P-selectin, ng/mL
(1) Dry-cured −5.00 −8.19 −1.80 0.003513
(2) Control −1.31 −4.60 2.10 0.461629
(1)–(2) −3.69 −7.36 0.02 0.062522
VCAM-1, ng/mL
(1) Dry-cured 3.23 −17.97 24.42 0.769504
(2) Control 3.41 −19.33 26.15 0.772709
(1)–(2) −0.19 −25.61 25.24 0.988745
MCP-1, pg/mL
(1) Dry-cured 5.45 −8.35 19.25 0.448144
(2) Control −14.39 −29.20 0.42 0.064524
(1)–(2) 19.84 3.28 36.40 0.023489
hs-IL6, pg/mL
(1) Dry-cured −0.60 −1.15 −0.05 0.037294
(2) Control −0.39 −0.96 0.19 0.199947
(1)–(2) −0.52 −0.77 −0.04 0.049448
BMI: Body Mass Index; VCAM-1: Vascular Cell Adhesion Molecule 1; MCP-1: Monocyte Chemoattractant Protein-1;
hs-IL6: high-sensitivity Interleukin 6.
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3.1. Plasmatic Markers
A comparison between plasma biochemical markers before and after dry-cured ham intake
is shown in Table 3 and Figure 2. After 4 weeks of regular dry-cured ham intake and adjusting for
a potential period effect, soluble P-selectin (sCD62P) concentration was markedly lower than in baseline
conditions (p = 0.0035). The mean difference of soluble P-selectin levels was still slightly decreased
between interventional and control periods (p = 0.0625). Besides, MCP-1 levels were found unaltered
after the interventional period, but when the cooked ham intake was included, a significant increase
in MCP-1 levels was observed (p = 0.0234). Decreased concentrations of the soluble inflammatory
mediator (IL6) were measured in plasma after the interventional period (p = 0.037). Such an effect was
still shown after adjusting with the control cooked ham period (p = 0.049). In contrast, there were no
significant differences in plasma concentrations of soluble VCAM-1 after dry-cured ham nor cooked
ham intake.
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Figure 2. Mean change relative to baseline time in soluble plasmatic marker levels in the interventional
and control groups. The values were compared after participants had ingested 80 g/day of dry-cured
ham or 100 g/day of cooked ham (n = 38) for 4 weeks (+95% confidence interval).
3.2. Effect on Platelet Activation
The regular consumption of bioactive peptides resulted in a significant decrease in P-selectin
(CD62P) expression by 11.17% (55.24 poi ts) in platelets stimulated with ADP (p = 0.0000272) (Table 4
and Figure 3). However, changes in th glycoprotein IIb/IIIα expression (PAC-1 monoclonal antibody
binding) did not change after the 30 days’ intervention (p = 0.447).
3.3. Effect on Monocytes Markers
There was no difference in the expression of surf ce ICAM-1 receptor between the two time points
in the different subtypes of monocytes. Similar data were also obtai ed for CD163 expression (Table 4).
However, expression of CD163 in Mon3 decreased significantly by 39% (p = 0.0000024) (Figure 3).
Besides, the expression levels of VCAM-1 receptor and CXCR4 were significantly higher for
all three subsets compared to baseline conditions (all p < 0.02). Dry-cured ham intake produced an
important increase of 343% in VCAM-1R levels in Mon 2 (p = 0.00075) (Figure 3). Expression levels of
TLR4 in the three monocytes subsets were also strongly affected after the intervention (all p < 0.05)
(Figure 3). Similarly, IL6R expression was down-regulated by 39% in Mon3 (p = 0.0000632) but these
differences did not reach statistical significance for the other two monocyte subsets, Mon1 and Mon2
(Table 4), although a trend was found for Mon2 (p = 0.0568).
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Figure 3. Mean change relative to baseline time in platelet and monocyte activation markers. The values
were compared after participants had ingested 80 g/day of dry-cured ham (n = 21) for 4 weeks
(+95% confidence interval).
Table 4. Cellular Parameters of the Volunteers (Baseline and Mean Difference after Consuming
Dry-Cured Ham for 4 Weeks).
n = 21
Baseline (before
Dry-Cured Ham) Mean Difference
Confidence Interval
p Value
Low 95% Upp 95%
Platelet activation markers
P-selectin expression, MFI 492.67 −55.24 −76.32 −34.16 0.0000272
PAC-1 binding, MFI 426.12 15.18 −26.33 56.68 0.447
Monocyte activation markers (n = 21)
Mon1_ICAM-1R, MFI 3799.22 552.94 −484.15 1590.03 0.275
Mon2_ICAM-1R, MFI 6325.33 −49.33 −989.93 891.26 0.912
Mon3_ICAM-1R, FI 4579.78 1114.66 −113.87 2343.20 0.072
Mon1_VCAM-1R, MFI 672.70 643.25 222.89 1063.61 0.00480
Mon2_VCAM-1R, MFI 1243.75 3022.30 1453.88 4590.72 0.00075
Mon3_VCAM-1R, MFI 2048.55 1917.80 397.35 3438.25 .01629
Mon1_CXCR4, MFI 1152.70 1019.90 545.43 1494.38 0.0000713 *
Mon2_CXCR4, MFI 24 .00 4244.17 1313.45 7174.89 0. 02603 *
Mon3_CXCR4, MFI 2215.55 9601.76 1498.90 17,704.61 0.0002743 *
Mon1_CD163, MFI 1376.2 340.70 −70.88 752.28 0.098
Mon2_CD163, MFI 1838.90 164.94 −392.83 722.70 0.540
Mon3_CD163, MFI 2606.90 −1016.48 −1325.88 −707.08 0.0000024
Mon1_TLR4, MFI 1050.57 261.05 −44.91 567.00 0.0411524 *
Mon2_TLR4, MFI 1915.72 2061.10 52.87 4069.33 0.0239622 *
Mon3_TLR4, MFI 1611.00 3266.19 468.86 6063.52 0.0082297 *
Mon1_IL6R, MFI 576.45 −24.60 −85.34 36.14 0.406
Mon2_IL6R, MFI 1186.40 −332.05 −674.78 10.68 0.0568
Mon3_IL6R, MFI 38 . −1475.70 −2074.37 −877.03 0. 0632
ICAM-1R: Intercellular Adhesion Molecule-1 Receptor; VCAM-1R: Vascular Cell Adhesion Molecule-1 Receptor;
TLR4: Toll-Like Receptor 4; IL6R: Interleukin 6 Receptor; MFI: Mean Fluorescence Intensity. * Data were log
transformed before analysis.
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4. Discussion
Dietary bioactives are compounds of food origin that safely deliver health benefits, although
their mechanisms of action are usually poorly understood. Generally, meat and meat products are not
ordinarily associated with health benefits [22]. However, in vitro tested health-promoting bioactive
peptides are naturally generated from meat proteins during curing or fermentation. Moreover, it is
a challenge for the food industry to identify the functionality of bioactives, in order to make products
healthier and, possibly to claim that they may be regarded as functional foods. Therefore, the aim
of this investigation was to evaluate the effect of the regular consumption of dry-cured pork ham
containing characterized active biopeptides among other possible bioactives on platelet activation,
monocytes phenotype and plasma markers of inflammation and activation.
The presence of naturally active biopeptides in the meat product was confirmed by a peptidomic
strategy using mass spectrometry techniques [19]. Cooked ham was chosen as the control product
because active biopeptides are not released during its manufacture, as confirmed here. To our
knowledge, no previous study has associated the regular consumption of meat peptides with in vivo
cellular changes, even though several in vitro studies suggested possible action mechanisms [17,23,24].
Impaired platelet function results in a higher degree of degranulation and translocation of
P-selectin (CD62P) to the outer plasmatic membrane, both of which have been related to CV
pathological conditions such as hypertension, diabetes, myocardial infarction, heart failure and
stroke [25]. Accordingly, P-selectin has also been proposed as a novel therapeutic target in vascular
disease [26]. One of the more significant findings to emerge from this study is that the intake of
dry-cured ham enriched in active biopeptides is related to a decrease in the platelet expression of this
activation marker, P-selectin. Moreover, the findings also point to a reduction of soluble P-selectin after
the interventional period, even adjusting with the cooked ham intake. This data also supports a role for
active biopeptides in modulating in vivo platelet function. The ability to inhibit platelet function has
previously been confirmed ex vivo in the presence of other vegetable bioactives [27]. Nonetheless, it is
unclear why this occurs or what role this response might play in pathological conditions, other than in
healthy individuals with normal-high non-treated hypertension. Thereby, the current study opens up
an interesting avenue for further research into the mechanism(s) of these dietary peptides in platelet
phenotype and function.
The roles of monocytes in CVD are diverse, including their involvement in inflammatory responses
and the regulation of the thrombogenic status. In experimental hypertension, monocytes increase their
adhesion to the endothelium integrins (ICAM-1, VCAM-1) through their receptors (ICAM-1R and
VCAM-1R). Moreover, monocytes have also been implicated in physiologically beneficial processes
related to the scavenging of pathological material, angiogenesis and repair through stromal derived
factor-1 (SDF1) binding to CXCR4. The diversity of monocytes functions can be partly attributed to the
existence of different monocytes subsets (Mon1, Mon2 and Mon3) that can be distinguished according
to specific phenotypic and functional properties [28]. In this line, the second major finding of the
current study was that the consumption of dry-cured ham impaired the basal expression of several
markers in circulating monocytes. For instance, the expression of the integrin α4 receptor (VCAM-1R)
and CXCR4 (SDF1 receptor) increased significantly in the three subtypes of monocytes. Recent
investigations found that VCAM-1R and CXCR4 in monocytes were higher in healthy volunteers
compared to individuals with coronary artery disease (CAD) [21], confirming an improvement of
the physiological status after the long-term consumption of dry-cured ham. CD163 and TLR4 are
proteins involved in immunity, scavenging and the recognition of antigens [29]. The TLR4 expression
also increased after the intervention in all the three monocyte subsets. The expression of CD163 was
higher after the intervention in the minority Mon3. Concerning the expression of IL6R, levels remained
unaltered after the intervention in the main subset Mon1 but it significantly decreased in Mon3 and
a trend was shown for Mon2, once more in agreement with previous results with healthy volunteers
towards CAD patients [21]. Whether IL6R levels decrease as a consequence of lower transcription
cannot be formally demonstrated here. Nonetheless, greater IL6 binding to IL6R might not be the case
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because the plasmatic levels of IL6 were substantially lower after the regular consumption of cured
meat adjusted with a potential period effect. Neither can the effects be attributed to observer bias or
lifestyle confounders. In relation to that, the current analysis also identified increased plasmatic MCP-1
levels, which regulate the migration of monocytes, between the intervention and control groups.
Taken together, those observations seem to suggest intake-dependent changes in monocytes and
an improvement in the inflammatory status.
Limitations
Differences in the molecular parameters were only shown after the interventional period of time.
However, plasmatic markers were analyzed after the intake of both meat products, allowing a valid
estimate of the dry-cured ham intake effect. Although irrelevant from the clinical point of view, it is
important to mention that volunteers took lower salt amounts during cooked ham intake (1 g/day
less), compared to the interventional period. The effect of dry-cured ham consumption on platelet and
monocytes phenotype cannot be directly attributed to active biopeptides; nonetheless, it is important
to underline the broad range of sequenced peptides contained in the dry-cured ham and absent in the
control product. The ideal quantity of biopeptides from any origin that would provide beneficial effects
in humans has not been determined; neither has the amount of biopeptides contained in the ham.
Nevertheless, the study was designed to involve the highest feasible daily intake of dry-cured meat.
5. Conclusions
As the era of molecular nutrition unfolds, a greater understanding of how these foods and
their components influence cellular mechanisms will surely arise. Current molecular approaches,
such as flow cytometry, can aid the scientific community in gaining a deeper understanding related
to the effects of active compounds over a variety of cell types, tissues and pathological conditions.
Such information will be critical in the development of healthier products for reducing the CV burden.
In particular, the present results lead to the conclusion that active biopeptides have potential therapeutic
effects in the vascular system, and help identify future molecular targets for the prevention of CV
risk factors in healthy individuals. In addition, whether these new categories of active compounds
affect platelet function, monocytes phenotype and inflammation requires further well-controlled
interventional studies. It is therefore envisaged that future in vitro experiments should try to confirm
the association of these factors and that in vivo studies will be carried out in patients with high CV risk.
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